Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$14.32 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.24 -0.08 (-0.56%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Keros Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
KROS 14.32 0.00(0.00%)
Will KROS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KROS
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KROS
ClearBridge Small Cap Strategy Q2 2025 Commentary
Noteworthy Friday Option Activity: KROS, TEAM, BYON
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
Major Shareholder Sells Off Keros Therapeutics Stock!
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls